INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 136 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2018. The put-call ratio across all filers is 0.51 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $8,322,464 | -10.8% | 131,435 | -23.7% | 0.33% | -8.2% |
| Q1 2023 | $9,333,890 | +2.3% | 172,371 | 0.0% | 0.36% | +2.9% |
| Q4 2022 | $9,121,873 | +13.7% | 172,371 | 0.0% | 0.34% | +5.2% |
| Q3 2022 | $8,020,000 | -42.3% | 172,371 | -29.2% | 0.33% | -39.9% |
| Q2 2022 | $13,895,000 | -21.9% | 243,437 | -16.3% | 0.55% | -12.6% |
| Q1 2022 | $17,802,000 | +43.8% | 290,936 | +23.0% | 0.62% | +57.0% |
| Q4 2021 | $12,376,000 | +2.3% | 236,447 | -27.1% | 0.40% | +2.3% |
| Q3 2021 | $12,094,000 | +46.1% | 324,401 | +60.0% | 0.39% | +44.6% |
| Q2 2021 | $8,276,000 | +4.9% | 202,756 | -12.8% | 0.27% | -0.7% |
| Q1 2021 | $7,888,000 | -32.3% | 232,476 | -36.5% | 0.27% | -33.7% |
| Q4 2020 | $11,644,000 | +381.6% | 366,176 | +288.6% | 0.41% | +349.5% |
| Q3 2020 | $2,418,000 | -0.0% | 94,238 | 0.0% | 0.09% | -1.1% |
| Q2 2020 | $2,419,000 | +67.1% | 94,238 | 0.0% | 0.09% | +41.5% |
| Q1 2020 | $1,448,000 | -55.2% | 94,238 | 0.0% | 0.06% | -46.7% |
| Q4 2019 | $3,233,000 | +1469.4% | 94,238 | +242.1% | 0.12% | +1255.6% |
| Q3 2019 | $206,000 | -71.2% | 27,548 | -50.0% | 0.01% | -69.0% |
| Q2 2019 | $715,000 | -46.7% | 55,096 | -50.0% | 0.03% | -47.3% |
| Q1 2019 | $1,342,000 | +6.9% | 110,193 | 0.0% | 0.06% | +1.9% |
| Q4 2018 | $1,255,000 | +66.0% | 110,193 | +216.2% | 0.05% | +100.0% |
| Q3 2018 | $756,000 | -89.6% | 34,850 | -81.4% | 0.03% | -90.9% |
| Q2 2016 | $7,290,000 | +39.6% | 187,800 | 0.0% | 0.30% | +34.2% |
| Q1 2016 | $5,221,000 | -48.3% | 187,800 | 0.0% | 0.22% | -39.3% |
| Q4 2015 | $10,102,000 | +68.2% | 187,800 | +25.2% | 0.37% | +69.4% |
| Q3 2015 | $6,006,000 | -17.2% | 150,000 | -34.0% | 0.22% | -17.9% |
| Q2 2015 | $7,258,000 | +102.6% | 227,164 | +51.4% | 0.26% | +85.2% |
| Q1 2015 | $3,582,000 | – | 150,000 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 675,000 | $26,203,000 | 7.44% |
| EcoR1 Capital, LLC | 244,950 | $9,509,000 | 3.75% |
| Redmile Group, LLC | 971,565 | $37,716,000 | 3.60% |
| Ghost Tree Capital, LLC | 120,000 | $4,658,000 | 1.34% |
| SENZAR ASSET MANAGEMENT, LLC | 144,624 | $5,614,304,000 | 1.22% |
| GREAT POINT PARTNERS LLC | 100,000 | $3,882,000 | 1.11% |
| BB BIOTECH AG | 700,000 | $27,174,000 | 1.07% |
| Rhenman & Partners Asset Management AB | 115,000 | $4,464,000 | 0.79% |
| Lisanti Capital Growth, LLC | 12,260 | $476,000 | 0.72% |
| Rock Springs Capital Management LP | 190,000 | $7,376,000 | 0.55% |